In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma

Oncotarget

Volumn 8, Issue 3, 2017, Pages 4079-4095

  Pessetto, Ziyan Y ^a   Chen, Bin ^b   Alturkmani, Hani ^a   Hyter, Stephen ^a   Flynn, Colleen A ^c   Baltezor, Michael ^c   Ma, Yan ^a   Rosenthal, Howard G ^c   Neville, Kathleen A ^d   Weir, Scott J ^a,c,e   Butte, Atul J ^b   Godwin, Andrew K ^a,c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^d ARKANSAS CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Auranofin; Drug repurposing; Ewing sarcoma; Ganetespib; High throughput screening

Indexed keywords

AURANOFIN; GANETESPIB; LUMINESPIB; ANTINEOPLASTIC AGENT; EWS-ERG FUSION PROTEIN, HUMAN; EWS-FLI FUSION PROTEIN; EWS1-WT1 FUSION PROTEIN, HUMAN; ONCOPROTEIN; RNA BINDING PROTEIN EWS; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FLI 1; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOINFORMATICS; CANCER INHIBITION; CANCER SURVIVAL; CELL GROWTH; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG POTENTIATION; DRUG SCREENING; DRUG SENSITIVITY; EWING SARCOMA; EWING SARCOMA CELL LINE; FEMALE; FLI1 GENE; GENE EXPRESSION; GENE SILENCING; IC50; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MOUSE; NONHUMAN; ONCOGENE; SINGLE DRUG DOSE; SURVIVAL RATE; CELL PROLIFERATION; CELL SURVIVAL; COMPUTER SIMULATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AURANOFIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMPUTER SIMULATION; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN VITRO TECHNIQUES; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; TRANSCRIPTION FACTORS; TRIAZOLES;

EID: 85012024851     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13385     Document Type: Article

References (83)

1. Ross KA, Smyth NA, Murawski CD, Kennedy JG. The biology of ewing sarcoma. ISRN Oncol. 2013; 2013: 759725 doi:10.1155/2013/759725.
2. Ordonez JL, Osuna D, Herrero D, de Alava E, Madoz-Gurpide J. Advances in Ewing's sarcoma research: where are we now and what lies ahead? Cancer Res. 2009; 69:7140-50. doi:10.1158/0008-5472.CAN-08-4041.
3. Rodriguez-Galindo C, Navid F, Liu T, Billups CA, Rao BN, Krasin MJ. Prognostic factors for local and distant control in Ewing sarcoma family of tumors. Ann Oncol. 2008; 19:814-20. doi:10.1093/annonc/mdm521.
4. Pinkerton CR, Bataillard A, Guillo S, Oberlin O, Fervers B, Philip T. Treatment strategies for metastatic Ewing's sarcoma. Eur J Cancer. 2001; 37:1338-44. doi:
5. Rodriguez-Galindo C, Liu T, Krasin MJ, Wu J, Billups CA, Daw NC, Spunt SL, Rao BN, Santana VM, Navid F. Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer. 2007; 110:375-84. doi:10.1002/cncr.22821.
6. Esiashvili N, Goodman M, Marcus RB, Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol. 2008; 30:425-30. doi:10.1097/MPH.0b013e31816e22f3.
7. Chaturvedi A, Hoffman LM, Welm AL, Lessnick SL, Beckerle MC. The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma. Genes Cancer. 2012; 3:102-16. doi:10.1177/1947601912457024.
8. Sankar S, Lessnick SL. Promiscuous partnerships in Ewing's sarcoma. Cancer Genet. 2011; 204:351-65. doi:10.1016/j.cancergen.2011.07.008.
9. Jedlicka P. Ewing Sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions. Int J Clin Exp Pathol. 2010; 3:338-47. doi:
10. Ahmed AA, Zia H, Wagner L. Therapy resistance mechanisms in Ewing's sarcoma family tumors. Cancer Chemother Pharmacol. 2014; 73:657-63. doi:10.1007/s00280-014-2392-1.
11. Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, Marcus K, Sailer S, Healey JH, Dormans JP, Weiss AR. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012; 30:4148-54. doi:10.1200/JCO.2011.41.5703.
12. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol. 2010; 11:184-92. doi:10.1016/S1470-2045(09)70286-4.
13. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, Sage J, Butte AJ. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med. 2011; 3: 96ra77. doi:10.1126/scitranslmed.3001318.
14. Vicent S, Sayles LC, Vaka D, Khatri P, Gevaert O, Chen R, Zheng Y, Gillespie AK, Clarke N, Xu Y, Shrager J, Hoang CD, Plevritis S, et al. Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo. Cancer Res. 2012; 72:5744-56. doi:10.1158/0008-5472.can-12-1097.
15. Giovannini M, Biegel JA, Serra M, Wang JY, Wei YH, Nycum L, Emanuel BS, Evans GA. EWS-erg and EWSFli1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations. J Clin Invest. 1994; 94:489-96. doi:10.1172/JCI117360.
16. Teicher BA, Bagley RG, Rouleau C, Kruger A, Ren Y, Kurtzberg L. Characteristics of human Ewing/PNET sarcoma models. Ann Saudi Med. 2011; 31:174-82. doi:10.4103/0256-4947.78206.
17. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res. 2012; 18:64-76. doi:10.1158/1078-0432.ccr-11-1000.
18. Inc. PL. RIDAURA® (auranofin) Capsules. 2011. (See Supplementary Material Reference 18).
19. Inc. XP. RIDAURA® Auranofin Capsules 3 mg product monograph. Retrieved from http://www.xediton.com/RIDAURA_PRODUCT%20MONOGRAPH.pdf. 2010. doi:
20. Giannini EH, Brewer EJ, Person DA. Blood gold concentrations in children with juvenile rheumatoid arthritis undergoing long-term oral gold therapy. Ann Rheum Dis. 1984; 43:228-31. doi:
21. Hirschfeld S, Ho PT, Smith M, Pazdur R. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. J Clin Oncol. 2003; 21:1066-73. doi:10.1200/JCO.2003.11.138.
22. Melnikova I. Rare diseases and orphan drugs. Nat Rev Drug Discov. 2012; 11:267-8. doi:10.1038/nrd3654.
23. (2013). Orphan Drug Act. In: FDA, ed. 21.
24. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs.
25. Pessetto ZY, Ma Y, Hirst JJ, von Mehren M, Weir SJ, Godwin AK. Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor. Mol Cancer Ther. 2014; 13:2276-87. doi:10.1158/1535-7163.mct-14-0043.
26. Pessetto ZY, Weir SJ, Sethi G, Broward MA, Godwin AK. Drug repurposing for gastrointestinal stromal tumor. Mol Cancer Ther. 2013; 12:1299-309. doi:10.1158/1535-7163. MCT-12-0968.
27. Weir SJ, DeGennaro LJ, Austin CP. Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. Cancer Res. 2012; 72:1055-8. doi:10.1158/0008-5472.can-11-3439.
28. Lipton SA, Nordstedt C. Partnering with Big Pharma-What Academics Need to Know.
29. Dudley JT, Schadt E, Sirota M, Butte AJ, Ashley E. Drug discovery in a multidimensional world: systems, patterns, and networks. J Cardiovasc Transl Res. 2010; 3:438-47. doi:10.1007/s12265-010-9214-6.
30. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP, Morgan AA, Sarwal MM, Pasricha PJ, Butte AJ. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med. 2011; 3: 96ra76. doi:10.1126/scitranslmed.3002648.
31. Yeh CT, Wu AT, Chang PM, Chen KY, Yang CN, Yang SC, Ho CC, Chen CC, Kuo YL, Lee PY, Liu YW, Yen CC, Hsiao M, et al. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respir Crit Care Med. 2012; 186:1180-8. doi:10.1164/rccm.201207-1180OC.
32. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, Opferman JT, Sallan SE, den Boer ML, Pieters R, Golub TR, Armstrong SA. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006; 10:331-42. doi:10.1016/j.ccr.2006.09.006.
33. Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, Zhang Z, Lapouble E, Grossetete-Lalami S, Rusch M, Reynaud S, Rio-Frio T, Hedlund E, et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 2014; 4:1342-53. doi:10.1158/2159-8290. CD-14-0622.
34. Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, Kiezun A, Carter SL, Shukla SA, Mehta SS, Thorner AR, de Torres C, Lavarino C, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014; 4:1326-41. doi:10.1158/2159-8290. CD-13-1037.
35. Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, Patidar R, Hurd L, Chen L, Shern JF, Liao H, Wen X, Gerard J, et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet. 2014; 10: e1004475. doi:10.1371/journal.pgen.1004475.
36. Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S, Tidwell ML, Greer J, Chung EJ, Lee MJ, Gore SD, Sausville EA, Zwiebel J, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 2007; 109:2781-90. doi:10.1182/blood-2006-05-021873.
37. Kummar S, Gutierrez M, Gardner ER, Donovan E, Hwang K, Chung EJ, Lee MJ, Maynard K, Kalnitskiy M, Chen A, Melillo G, Ryan QC, Conley B, et al. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res. 2007; 13:5411-7. doi:10.1158/1078-0432.CCR-07-0791.
38. Gore L, Rothenberg ML, O'Bryant CL, Schultz MK, Sandler AB, Coffin D, McCoy C, Schott A, Scholz C, Eckhardt SG. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res. 2008; 14:4517-25. doi:10.1158/1078-0432.CCR-07-1461.
39. Hauschild A, Trefzer U, Garbe C, Kaehler KC, Ugurel S, Kiecker F, Eigentler T, Krissel H, Schott A, Schadendorf D. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-(4-[(2-aminophenyl)-carbamoyl]-benzyl)-carbamate in pretreated metastatic melanoma. Melanoma Res. 2008; 18:274-8. doi:10.1097/CMR.0b013e328307c248.
40. Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer. 2012; 106:77-84. doi:10.1038/bjc.2011.527.
41. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011; 1:598-607. doi:10.1158/2159-8290.CD-11-0214.
42. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB. Randomized phase II, double-blind, placebocontrolled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013; 31:2128-35. doi:10.1200/JCO.2012.43.7251.
43. Chen X, Shi X, Wang X, Liu J. Novel use of old drug: Antirheumatic agent auranofin overcomes imatinib-resistance of chronic myeloid leukemia cells. Cancer Cell Microenviron. 2014; 1. doi:10.14800/ccm.415.
44. Chen X, Shi X, Zhao C, Li X, Lan X, Liu S, Huang H, Liu N, Liao S, Zang D, Song W, Liu Q, Carter BZ, et al. Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and-independent mechanisms. Oncotarget. 2014; 5:9118-32. doi: 10.18632/oncotarget.2361.
45. Madeira JM, Bajwa E, Stuart MJ, Hashioka S, Klegeris A. Gold drug auranofin could reduce neuroinflammation by inhibiting microglia cytotoxic secretions and primed respiratory burst. J Neuroimmunol. 2014. doi:10.1016/j. jneuroim.2014.08.615.
46. Cox AG, Brown KK, Arner ES, Hampton MB. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol. 2008; 76:1097-109. doi:10.1016/j.bcp.2008.08.021.
47. Fan C, Zheng W, Fu X, Li X, Wong YS, Chen T. Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo. Cell Death Dis. 2014; 5: e1191. doi:10.1038/cddis.2014.132.
48. Liu C, Liu Z, Li M, Li X, Wong YS, Ngai SM, Zheng W, Zhang Y, Chen T. Enhancement of auranofin-induced apoptosis in MCF-7 human breast cells by selenocystine, a synergistic inhibitor of thioredoxin reductase. PLoS One. 2013; 8: e53945. doi:10.1371/journal.pone.0053945.
49. Liu JJ, Liu Q, Wei HL, Yi J, Zhao HS, Gao LP. Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells. Pharmazie. 2011; 66:440-4. doi:
50. Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med. 2007; 42:872-81 doi:10.1016/j.freeradbiomed.2006.12.021.
51. Pratesi A, Gabbiani C, Michelucci E, Ginanneschi M, Papini AM, Rubbiani R, Ott I, Messori L. Insights on the mechanism of thioredoxin reductase inhibition by gold N-heterocyclic carbene compounds using the synthetic linear selenocysteine containing C-terminal peptide hTrxR(488-499): an ESI-MS investigation. J Inorg Biochem. 2014; 136:161-9. doi:10.1016/j. jinorgbio.2014.01.009.
52. Di Sarra F, B. F, Bini R, Saielli G, Bagno A. Reactivity of Auranofin with Selenols and Thiols-Implications for the Anticancer Activity of Gold(I) Compounds. Eur J Inorg Chem. 2013; 2013:2718-27. doi:10.1002/ejic.201300058.
53. Rigobello MP, Messori L, Marcon G, Agostina Cinellu M, Bragadin M, Folda A, Scutari G, Bindoli A. Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions. J Inorg Biochem. 2004; 98:1634-41. doi:10.1016/j.jinorgbio.2004.04.020.
54. Gromer S, Arscott LD, Williams CH, Jr., Schirmer RH, Becker K. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem. 1998; 273:20096-101. doi:
55. Wang Y, Hill KS, Fields AP. PKCiota maintains a tumorinitiating cell phenotype that is required for ovarian tumorigenesis. Mol Cancer Res. 2013; 11:1624-35. doi:10.1158/1541-7786.MCR-13-0371-T.
56. Roder C, Thomson MJ. Auranofin: repurposing an old drug for a golden new age. Drugs R D. 2015; 15:13-20. doi:10.1007/s40268-015-0083-y.
57. Kean WF, Kean IR. Clinical pharmacology of gold. Inflammopharmacology. 2008; 16:112-25. doi:10.1007/s10787-007-0021-x.
58. Fiskus W, Saba N, Shen M, Ghias M, Liu J, Gupta SD, Chauhan L, Rao R, Gunewardena S, Schorno K, Austin CP, Maddocks K, Byrd J, et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res. 2014; 74:2520-32. doi:10.1158/0008-5472.CAN-13-2033.
59. Park SH, Lee JH, Berek JS, Hu MC. Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53. Int J Oncol. 2014; 45:1691-8. doi:10.3892/ijo.2014.2579.
60. Kim NH, Park HJ, Oh MK, Kim IS. Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells. BMB Rep. 2013; 46:59-64. doi:
61. Nakaya A, Sagawa M, Muto A, Uchida H, Ikeda Y, Kizaki M. The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kappaB activity. Leuk Res. 2011; 35:243-9. doi:10.1016/j.leukres.2010.05.011.
62. Liu N, Li X, Huang H, Zhao C, Liao S, Yang C, Liu S, Song W, Lu X, Lan X, Chen X, Yi S, Xu L, et al. Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget. 2014; 5:5453-71. doi: 10.18632/oncotarget.2113.
63. Tepperman K, Finer R, Donovan S, Elder RC, Doi J, Ratliff D, Ng K. Intestinal uptake and metabolism of auranofin, a new oral gold-based antiarthritis drug. Science. 1984; 225:430-2. doi:
64. Kean WF, Hart L, Buchanan WW. Auranofin. Br J Rheumatol. 1997; 36:560-72. doi:
65. Jatoi A, Radecki Breitkopf C, Foster NR, Block MS, Grudem M, Wahner Hendrickson A, Carlson RE, Barrette B, Karlin N, Fields AP. A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients. Oncology. 2015; 88:208-13. doi:10.1159/000369257.
66. Du X, Li Y, Jing X, Zhao L. Effect of a heat shock protein 90-specific inhibitor on the proliferation and apoptosis induced by VEGF-C in cervical cancer cells. Exp Ther Med. 2014; 8:1559-64. doi:10.3892/etm.2014.1930.
67. Singh A, Singh A, Sand JM, Bauer SJ, Bin Hafeez B, Meske L, Verma AK. Topically Applied Hsp90 Inhibitor 17AAG Inhibits Ultraviolet Radiation-Induced Cutaneous Squamous Cell Carcinomas. J Invest Dermatol. 2014. doi:10.1038/jid.2014.460.
68. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 2012; 1823:742-55. doi:10.1016/j.bbamcr.2011.10.008.
69. Yu Y, Szczepek AJ, Haupt H, Mazurek B. Geldanamycin induces production of heat shock protein 70 and partially attenuates ototoxicity caused by gentamicin in the organ of Corti explants. J Biomed Sci. 2009; 16: 79. doi:10.1186/1423-0127-16-79.
70. Proia DA, Bates RC. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. Cancer Res. 2014; 74:1294-300. doi:10.1158/0008-5472.CAN-13-3263.
71. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall F, Aherne W, Rowlands M, Hayes A, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008; 68:2850-60. doi:10.1158/0008-5472.CAN-07-5256.
72. Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res. 2012; 18:4973-85. doi:10.1158/1078-0432.CCR-11-2967.
73. Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita M, Papadimitrakopoulou V, Pluard T, Samuel TA, Akimov M, Quadt C, Fernandez-Ibarra C, Lu H, et al. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res. 2013; 19:3671-80. doi:10.1158/1078-0432.CCR-12-3404.
74. Martinez-Ramirez A, Rodriguez-Perales S, Melendez B, Martinez-Delgado B, Urioste M, Cigudosa JC, Benitez J. Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques. Cancer Genet Cytogenet. 2003; 141:138-42. doi:
75. Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P, Kovar H. A molecular function map of Ewing's sarcoma. PLoS One. 2009; 4: e5415. doi:10.1371/journal. pone.0005415.
76. Hancock JD, Lessnick SL. A transcriptional profiling metaanalysis reveals a core EWS-FLI gene expression signature. Cell Cycle. 2008; 7:250-6. doi:
77. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004; 24:7275-83. doi:10.1128/MCB.24.16.7275-7283.2004.
78. Schaefer KL, Eisenacher M, Braun Y, Brachwitz K, Wai DH, Dirksen U, Lanvers-Kaminsky C, Juergens H, Herrero D, Stegmaier S, Koscielniak E, Eggert A, Nathrath M, et al. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer. 2008; 44:699-709. doi:10.1016/j.ejca.2008.01.020.
79. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006; 313: 1929-35. doi:
80. Inglese J, Shamu CE, Guy RK. Reporting data from high-throughput screening of small-molecule libraries. Nature chemical biology. 2007; 3:438-41. doi:10.1038/nchembio0807-438.
81. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70:440-6. doi:10.1158/0008-5472.can-09-1947.
82. Chou TC. The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development. Am J Cancer Res. 2011; 1:925-54. doi:
83. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58:621-81 doi:10.1124/pr.58.3.10.